Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Silodosin-d4
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang

1426173-86-5

1426173-86-5 structure

Name: Silodosin-d4
Chemical Name: Silodosin-d4
CAS Number: 1426173-86-5
Molecular Formula: C₂₅H₂₈D₄F₃N₃O₄
Molecular Weight: 499.559
Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
Create Date: 2021-06-21 18:17:46
Modify Date: 2024-01-13 15:08:45
Silodosin-d4 (KAD 3213-d4) is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH[1][3].

Name	Silodosin-d4
Synonyms	SILODOSIN-D4 1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl-1,1,2,2-d4]amino]propyl]- 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy](2H4)ethyl}amino)propyl]-7-indolinecarboxamide

Description	Silodosin-d4 (KAD 3213-d4) is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH[1][3].
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Maxime Rossi , Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010; 4: 291–297. [3]. Villa L, et al. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.Br J Pharmacol. 2013 May;169(1):230-8. [4]. Osman NI, et al.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Expert Opin Pharmacother. 2012 Oct;13(14):2085-96. [5]. Kawahara T, et al. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.Am J Cancer Res. 2015 Sep 15;5(10):2959-68. eCollection 2015.

Density	1.2±0.1 g/cm3
Boiling Point	601.4±55.0 °C at 760 mmHg
Molecular Formula	C₂₅H₂₈D₄F₃N₃O₄
Molecular Weight	499.559
Flash Point	317.5±31.5 °C
Exact Mass	499.259613
LogP	2.52
Vapour Pressure	0.0±1.8 mmHg at 25°C
Index of Refraction	1.552

1426173-86-5	160970-64-9
1051374-52-7	1453221-45-8
160970-54-7	1803448-63-6
1798342-21-8	1277178-52-5
1277178-53-6	879292-24-7
1158522-08-7	2229441-95-4
2229429-32-5	2228920-61-2
82078-42-0	2171956-60-6
2171307-96-1	2150077-94-2
940364-43-2	134104-43-1